Abstract 546P
Background
More than 70% of patients with T1 colorectal cancer (CRC) undergo a radical surgery involving lymph node dissection, despite the presence of lymph node metastasis (LNM) being observed in only ∼10% of cases. To reduce unnecessary radical surgery, we developed a multimodal artificial intelligence (AI) system to identify T1 CRC at risk for LNM.
Methods
We analyzed 402 CRC patients from two independent multicenter cohorts, including a training (n = 219) and a validation cohort (n = 183). Proteomics dataset from tumor tissue were identified and quantified using LC-MS/MS analysis. Multiple pathomics features were extracted from whole H&E slides with patch-level convolutional neural network training in weakly supervised manner. Clinicopathological characteristics included age, tumor size, location, lymphatic and vascular invasion, perineural invasion, histologic grade, and CEA. A machine-learning artificial neural network using proteomics, pathomics and clinicopathological features was developed.
Results
LNM were detected in 78 out of 219 patients (35.6%) within the training cohort and in 29 out of 183 patients (15.8%) within the validation cohort. A panel of six protein biomarkers (OSBPL5, ATAD2, BAIAP2, MANBA, ITPR2, ARHGAP5) screened by proteomics was quantified by immunohistochemistry and subsequently integrated into the AI system. In the validation cohort, the multimodal AI system achieved robust classification of LNM status, yielding an AUC of 0.978. In comparison, the guideline-based model exhibited an AUC of 0.717 for identifying LNM (P < 0.001).
Conclusions
The AI system integrating deep learning-proteomics, pathomics and clinicopathological features robustly identifies T1 CRC patients at risk of LNM in a preoperative setting. The multimodal AI system would improve clinical practice by alleviating the burden of unnecessary overtreatment for T1 CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jianmin Xu.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
393P - A phase II study to evaluate the efficacy and safety of TSL-1502 capsules in breast cancer patients with germline BRCA mutations
Presenter: Bo Lan
Session: Poster session 15
394P - Quantitative standardized high sensitivity (HS)-HER2 testing predicts outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC)
Presenter: Paolo Tarantino
Session: Poster session 15
395P - Receptor status heterogeneity during metastatic breast cancer treatment
Presenter: Sandra Geurts
Session: Poster session 15
396P - Evaluation of MUC1-C/CD3 biparatopic-bispecific (BPBS) T cell engager as an immunotherapeutic agent for the treatment of MUC1-expressing metastatic breast cancer (mBC)
Presenter: Ravi Jasuja
Session: Poster session 15
397P - Survival of de novo metastatic breast cancer according to biomarker status in Denmark and Norway: A register-based cohort study
Presenter: Johan Liseth Hansen
Session: Poster session 15
398P - Age and ethnic-driven molecular and clinical disparity of East Asian breast cancers
Presenter: Ji Yoon Lee
Session: Poster session 15
399P - Treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States
Presenter: Shanu Modi
Session: Poster session 15
400P - LncRNA-LINC00294 functions as a ceRNA in regulating JUP through competitively binding to miR-485-5p in breast cancer
Presenter: Ting Yang
Session: Poster session 15
Resources:
Abstract
401P - Evaluation of HER2 scoring in breast carcinoma-stained whole slide images
Presenter: Céline Bossard
Session: Poster session 15
402P - Inflammatory biomarkers for predicting the efficacy of immunotherapy in advanced breast cancer
Presenter: Kuikui Jiang
Session: Poster session 15